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Atherosclerosis is the underlying pathological process of
most cardiovascular disease. A critical component of the
“response to retention” hypothesis of atherogenesis is proteo-
glycan/low density lipoprotein (LDL) binding. Transforming
growth factor  (TGF-) is present in atherosclerotic lesions,
regulates vascular smooth muscle cell (VSMC) proteoglycan
synthesis via an unknown signaling pathway, and increases pro-
teoglycan/LDL binding. This pathway was investigated using
the activin receptor-like kinase 5 (ALK5) inhibitor SB431542
and inhibitors of p38 MAP kinase as a possible downstream or
alternative mediator. TGF- stimulated and SB431542 inhib-
ited the phosphorylation of Smad2/3. In human VSMC, TGF-
increased [35S]sulfate incorporation into proteoglycans associ-
atedwith a 19% increase in glycosaminoglycan (GAG) chain size
by size exclusion chromatography. SB431542 caused a
concentration-dependent decrease in TGF--mediated
[35S]sulfate incorporation with 92% inhibition at 3M. Two dif-
ferent p38MAPkinase inhibitors, SB203580 and SB202190, but
not the inactive analogue SB202474, concentration-
dependently blocked TGF--mediated [35S]sulfate incorpora-
tion. TGF- increased [3H]glucosamine incorporation into gly-
cosaminoglycans by 180% and [35S]Met/Cys incorporation into
proteoglycan core proteins by 35% with both effects completely
inhibited by SB431542. Blocking both Smad2/3 and p38 MAP
kinase pathways prevented the effect of TGF- to increase pro-
teoglycan to LDLbinding. TGF-mediates its effects on proteo-
glycan synthesis in VSMCs via the ALK5/Smad2/3 phosphoryl-
ation pathway as well as via the p38 MAP kinase signaling
cascade. Further studies of downstream pathways controlling
proteoglycan synthesis may identify potential therapeutic
targets for the prevention of atherosclerosis and cardiovascu-
lar disease.
Cardiovascular disease is currently the leading cause of death
and illness globally (1, 2). Atherosclerosis is the underlying
cause of this growing burden of cardiovascular disease (3),
which results in conditions such as heart attack and stroke (4).
Current therapies are based mostly on reducing risk factors
such as hypercholesterolemia, but none achieves greater than 30%
efficacy in clinical trials (5). No therapy directed at the vessel cur-
rently exists, but it is postulated that a vessel wall-directed therapy
may act synergistically with a risk factor-directed strategy to
reduce the progression of atherosclerosis.
Nakashima et al. (6) have recently provided definitive evi-
dence that human atherosclerosis commences with the deposi-
tion of lipid in the outer area of diffuse intimal thickenings;
furthermore, they show that this retention and deposition are
associated with expression of the proteoglycan, biglycan.
Lipoproteins bind to GAG2 and not core proteins (7), and thus
changes in GAG structure are most likely responsible for lipid
binding and retention. TGF- is strongly implicated in athero-
sclerosis (8). We have demonstrated that TGF- elongates
GAG chains on (VSM)-derived proteoglycans; these GAG
chains, as intact proteoglycans or free GAG chains, show
enhanced binding to human LDL (7).
Inhibition of GAG elongation represents a potential new
class of agents to prevent lipid deposition and atherosclerosis.
Hence a detailed knowledge of the agonists and the signaling
pathways that control GAG synthesis and structure is required
to provide information to allow for the rational development of
an agent that may be specific for inhibiting GAG elongation in
VSM.
TGF- transduces its effects from the cell membrane to the
nucleus through distantly related but structurally similar trans-
membrane Ser/Thr kinase receptors known as type I receptors
(TR-I/ALK5), constitutively active type II receptors (TR-II)
(9, 10), and their downstream effectors, known as Smad pro-
teins (11–14). In arterial smooth muscle cells TGF- up-regu-
lates biglycan mRNA (15), and in the pancreatic cell line
PANC-1, TGF--induced biglycan up-regulation has been
demonstrated to bemediated by p38MAP kinase signaling (16,
17). Recent progress in discovering the TGF- signaling cas-
cade makes it possible to attempt therapeutic strategies by dis-
rupting the signaling cascade (18). Nothing is known of the
TGF- signaling pathway that controls GAG synthesis in VSM.
We addressed the question of whether the TGF- receptor sig-
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naling pathway involving Smad 2/3 phosphorylation is involved
in the regulation of GAG chain synthesis in VSM and whether
p38 MAP kinase signaling is involved. We further evaluated
whether the TGF--mediated enhancement of LDL binding is
prevented by inhibiting the TGF- signaling pathway.
EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s modified Eagle’s medium (DMEM)
was from Invitrogen Corp., fetal bovine serum (FBS) and peni-
cillin-streptomycin-fungizone solution from CSL Ltd., and
trypsin-versene from JRH Biosciences Inc. 90-mm and 60-mm
plates, 75-cm3 flasks, and 24-well plates were from BD Bio-
sciences. Human TGF- and anti-human TGF-1/2/3 mono-
clonal antibody were from R&D Systems, Minneapolis, MN.
PDGF, SB431542, 6-amino caproic acid, benzamidine hydro-
chloride, methyl--D-xylopyranoside (xyloside), DEAE-Sepha-
cel, Sepharose CL-6B, proteinase K, sodium orthovanadate,
and sodium borohydride were from Sigma. Imatinib was pur-
chased as Glivec capsules from Novartis. The specific p38
inhibitors SB203580 and SB202190 and the negative control
inhibitor SB202474 were purchased from Calbiochem. Sulfur-
35-Na2SO4 ([35S]sulfate), Tran35S-label ([35S]Met/Cys), D-glu-
cosamine-HCL, [6-3H] ([3H]glucosamine), and [3H]thymidine
were from MP Biomedicals. Cetyl pyridinium chloride (CPC)
was from Unilab Chemicals and Pharmaceuticals. Whatman
No. 3MM chromatography paper was from Biolab. Instagel-
plus scintillation fluid was from PerkinElmer Life Sciences,
Poly-Prep columns from Bio-Rad, and BCA protein assay from
Pierce-Perbio. Rainbow 14C-methylated protein molecular
weight marker was fromAmersham Biosciences. Smoothmus-
cle -actin antibody was from Dako and phospho-Smad2/3
(Ser465/467) rabbit polyclonal antibody from chemicon. The
ECLWestern blotting analysis system, HyperfilmTMECL, anti-
rabbit IgG, and anti-mouse IgG were from Amersham Bio-
sciences.
Cell Culture—Human internal mammary artery and saphe-
nous vein VSMCs were derived from discarded vessels at the
AlfredHospital approved byAlfredHospital EthicsCommittee.
Cells were maintained in DMEM supplemented with low glu-
cose (5 mM), 10% FBS, and antibiotics. For experimentation,
cells between passages 6 and 15 were cultured. Confluent cul-
tures were deprived of serum by incubation in DMEM low glu-
cose with 0.1% FBS for 48 h prior to treatment.
Quantitation of Radiolabel Incorporation into Proteoglycans—
Quiescent cells were treated in 5 mM glucose-DMEM, 0.1%
FBS, 0.1%Me2SOwith SB431542 (3 M), SB203580 (1–10 M),
SB202190 (1–10 M), or SB202474 (1–10 M) and exposed to
[35S]sulfate (50–100 Ci/ml) or [3H]glucosamine (10 Ci/ml)
under basal conditions or in the presence of TGF- (2 ng/ml)
for 24 h unless stated otherwise. Secreted proteoglycans were
harvested, and radiolabel incorporation into proteoglycans was
quantitated using the CPC precipitation assay (19).
Chemical Cleavage of GAG Chains—Human VSMCs were
rendered quiescent and treated in 0.5mlDMEM, 0.1%FBSwith
SB431542 (3 M) under basal conditions and in the presence of
TGF- (2 ng/ml) for 4 h prior to the addition of [35S]sulfate (50
Ci/ml) for a further 24 h. Secreted proteoglycans were har-
vested, isolated, and concentrated as described previously (20).
To cleave the GAG chains chemically through a -elimination
reaction, pelleted proteoglycans were treated with sodium
borohydride (1 M) in NaOH (50 mM) for 24 h at 45 °C. The
reaction was terminated with glacial acetic acid.
Synthesis of Xyloside-initiated GAG Chains—Quiescent
human VSMCs were treated in 0.5 ml DMEM, 0.1% FBS sup-
plementedwithmethyl-D-xylopyranoside (xyloside) (0.5mM)
with SB431542 (3M) under basal conditions in the presence of
TGF- (2 ng/ml) for 4 h prior to the addition of [35S]sulfate (50
Ci/ml) for a further 24 h. Secreted proteoglycans were har-
vested, isolated, and concentrated as described previously (20).
Size Analysis of Proteoglycan/GAGLength by SDS-PAGE and
Size Exclusion Chromatography—Proteoglycans, cleaved GAG
chains, and xyloside-associatedGAGchainswere sized by SDS-
PAGE as described previously (19). Cleaved GAG chains and
xyloside-associated GAG chains were sized on Sepharose
CL-6B columns eluted in guanidine buffer as described previ-
ously (21). Data were standardized by calculating Kav values.
Thymidine Incorporation into DNA—VSMCs were treated
with PDGF (50 ng/ml) and other agents for 16 h, after which
time [3H]thymidine (1Ci/ml) was added for 3 h at 37 °C. Cells
were washed with ice-cold Dulbecco’s phosphate-buffered
saline (with Ca2 and Mg2), incubated on ice for 30 min with
0.2 M HClO4 to precipitate DNA and then washed with HClO4.
Cells were digested by the addition of 0.2 M NaOH for 1 h at
37 °C, and the reaction was neutralized using 6% acetic acid.
Radioactive incorporation was assessed on a liquid scintillation
counter.
Neutralization of TGF- with anti-TGF-1/2/3 Antibody—
VSMCs were incubated with anti-human-TGF-1/2/3 mono-
clonal antibody (1–50-fold molar excess) for 40 min prior to
treatment with growth factor and radiolabeling to determine
the concentration of antibody required to neutralize TGF-.
Mouse IgGwas used as an isotype control. In subsequent exper-
iments, a 20-fold molar excess of anti-TGF-1/2/3 antibody
was used.
Western Blotting—Total cell lysates were resolved on 10%
SDS-PAGE and transferred onto polyvinylidene difluoride.
Membranes were blocked with 5% skimmilk powder and incu-
bated with anti-phosphorylated Smad2/3 (pSmad2/3) rabbit
polyclonal antibody followed by horseradish peroxidase-anti-
rabbit IgG and ECL detection. Blots from three experiments
were quantified by densitometry using NIH ImageJ software.
Proteoglycan/LDL Binding by Gel Mobility Shift Assay—Hu-
man VSMCs were cultured, rendered quiescent as described,
and treated with SB431542 (3 M) or SB202190 (10 M) in the
presence of TGF- (2 ng/ml) for 12 h, at which time fresh treat-
ments were added with [35S]Met/Cys (50 Ci/ml) to radiolabel
proteoglycan core proteins (37 °C, 24 h). The secreted proteo-
glycans were harvested and isolated as described and dialyzed
into a physiological buffer (20 mM MOPS, 140 mM NaCl, 5 mM
CaCl2, 2 mMMgCl2, pH 7.4). Increasing concentrations of LDL
(0–0.5mg/ml) purified fromhuman blood (22) were incubated
with equal counts (1250 cpm) of proteoglycans for 1 h at 37 °C.
Samples were run on flat-bed agarose gels (0.7%) as described
previously (23).
Statistical Analysis—Normalized data are presented as the
mean  S.E. of three independent experiments conducted in
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triplicate unless stated otherwise. Data were analyzed for sta-
tistical significance using a one-way analysis of variance
(ANOVA), a two-way ANOVA, or a Student’s paired t test as
stated.
RESULTS
Smad and p38MAPKinase-mediated Proteoglycan Synthesis
in VSMC—To determine the extent of TGF-/ALK5-mediated
proteoglycan synthesis in human VSMC, we used the ALK5
inhibitor SB431542 (24). Cells were treated with TGF- (2
ng/ml) in the presence of SB431542 (0–3 M). SB431542
showed a concentration-dependent decrease of TGF--medi-
ated [35S]sulfate incorporation into secreted proteoglycans
(Fig. 1A). [35S]Sulfate incorporation in the presence of TGF-
was normalized to 100% for its effect at 10 M and SB431542 at
3 M decreased TGF--mediated [35S]sulfate incorporation by
92% (Fig. 1A). The IC50 value was determined to be 0.78 M
(comparable to kinase assay IC50 data from the supplier).
SB431542 at 3 M showed near maximum inhibition with no
decrease in cell numbers and was used for subsequent experi-
ments. Separation of proteoglycans on SDS-PAGE showed a
concentration-dependent increase in electrophoretic mobility
in the presence of SB431542 relative to TGF- treatment alone
(Fig. 1B), indicating a concentration-dependent decrease in
proteoglycan size upon ALK5 inhibition with SB431542. In the
classic TGF- signaling pathway, the effects of TGF- are
mediated via phosphorylation of Smad2/3 by ALK5 (11). We
determined the level of expression of pSmad2/3 protein in
whole cell lysates of human VSMC by Western blot. An 58-
kDa band corresponding to pSmad2/3 was observed in control
cells (Fig. 1C, lane 1) indicating the presence of pSmad2/3
under basal conditions. The pSmad2/3 band intensity inTGF-
(2 ng/ml)-treated cells (Fig. 1C, lane 3) was increased signifi-
cantly versus control (24 5%, p 0.01), indicating stimulation
of Smad2/3 phosphorylation. Treatment with the ALK5 inhib-
itor SB431542 (3 M) abolished the pSmad2/3 band in both
control cells and TGF--treated cells. These results demon-
strate that in humanVSMCSB431542 inhibits phosphorylation
of Smad2/3 byALK5 in the presence of TGF-, confirming that
SB431542 is able to effectively inhibit the classic TGF- Ser/
Thr kinase signaling pathway.
Recently p38MAP kinase was demonstrated to regulate big-
lycan expression (16). Todeterminewhether p38MAPkinase is
a mediator of ALK5 signaling in GAG elongation, in our cells
we used two inhibitors, SB203580 and SB202190, that specifi-
cally block activity of p38MAP kinase but not ALK5 at concen-
trations 10 M (25). Both inhibitors concentration-depend-
ently blocked TGF--mediated [35S]sulfate incorporation into
secreted proteoglycans (Fig. 2A) with a maximum decrease of
50% at 10M SB203580 (p 0.01) and 80% at 10M SB202190.
There was no significant inhibition observed with the negative
control inhibitor SB202474 (Fig. 2A). Separation of proteogly-
cans on an SDS-polyacrylamide gel showed an increase in elec-
trophoretic mobility of biglycan in the presence of either 10M
SB203580 or SB202190 relative to TGF- treatment alone (Fig.
2B, lane 3 versus lanes 4/5 and 6/7), indicating that inhibition of
p38MAPkinase activity by either inhibitor is sufficient to inter-
fere with GAG synthesis in VSMC.
To assess whether the change in biglycan size we observed
was because of alterations in GAG length, we chemically
cleaved the GAG chains from proteoglycan core proteins. In
the presence of TGF- the cleaved GAG chains showed a
decrease in electrophoretic mobility compared with control,
indicating an increased size (Fig. 2C, lane 2 versus 3). Elec-
trophoretic mobility of GAG chains in TGF--treated cells
FIGURE 1. Determination of the role of ALK5 activity in TGF--mediated
proteoglycan synthesis in human VSMCs using the ALK5 inhibitor
SB431542. A, VSMCs were treated with TGF- (2 ng/ml) in the presence of
SB431542 (0–3 M) and radiolabeled with [35S]sulfate (50 Ci/ml) for 24 h.
Medium containing secreted proteoglycans was spotted onto chromatogra-
phy paper, and CPC was precipitated to assess radiolabel incorporation into
proteoglycans. Normalized data are shown as the mean  S.E. from two
experiments in triplicate. B, secreted proteoglycans were isolated using ion-
exchange chromatography (DEAE-Sephacel) and concentrated by ethanol
precipitation. Electrophoretic mobility of proteoglycans was assessed by
SDS-PAGEona4–13%acrylamidegradientgel. A representativegel is shown.
C, inhibitory effects of SB431542 on TGF-/ALK5-mediated Smad2/3 phos-
phorylation in human VSMCs. VSMCs were treated with TGF- (2 ng/ml) and
SB431542 (3 M) for 24 h. Cell lysates were collected, and proteins were
resolved by SDS-PAGE on a 10% acrylamide gel and transferred onto a poly-
vinylidene difluoride membrane. The membrane was incubated with anti-
phospho-Smad2/3 rabbit polyclonal antibody (1:500 dilution) overnight at
4 °C followed by incubation with anti-rabbit IgG (1:5000 dilution) for 1 h at
room temperature. The membrane was then reprobed with anti-smooth
muscle -actin mouse monoclonal antibody (1:1000 dilution) for 1 h at
room temperature followed by incubation with anti-mouse IgG (1:5000
dilution) for 1 h.
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was inhibited to control levels in the presence of 10 M
SB203580 or 10 M SB202190 (Fig. 2C). SB202474 had no
detectable effect on TGF--mediated GAG elongation. The
results with the p38 inhibitors clearly demonstrate that
TGF--induced GAG elongation in VSMC is dependent on
p38 MAP kinase signaling. Taken together with our earlier
findings, this indicates that TGF- signals via ALK5/
Smad2/3 and p38 MAP kinase to induce GAG elongation in
human VSMC.
Temporal Effects of SB431542 on TGF-/ALK5-mediated
Proteoglycan Synthesis in Human VSMCs—Subsequent exper-
iments focused specifically on ALK5/Smads to determine the
extent of changes that signaling via these molecules pro-
duces in VSMC proteoglycans. We undertook a time course
study of ALK5 inhibition of TGF--mediated sulfate incor-
poration. SB431542 (3 M) decreased TGF- (2 ng/ml)-me-
diated [35S]sulfate incorporation to control levels (Fig. 3A).
TGF- caused a decrease in electrophoretic mobility, indi-
cating an increase in proteoglycan size, within 12 h of stim-
ulation (Fig. 3B). No change in the electrophoretic mobility
of proteoglycans from TGF--treated cells was observed in
the presence of SB431542 (Fig. 3B, lanes 6–9), suggesting
that the action of SB431542 occurs prior to the action of
TGF- on proteoglycan synthesis and therefore earlier than
12 h.
Effects of TGF- on GAG Synthesis in Human VSMCs Using
the ALK5 Inhibitor SB431542 and Glucosamine as an Alterna-
tive Radiolabel—Using the radiolabeled monosaccharide
[3H]glucosamine we confirmed the inhibitory effects of
SB431542 on VSMC proteoglycans. TGF- (2 ng/ml) caused a
180% increase in [3H]glucosamine incorporation compared
with control (p 0.01) indicating an increase inGAGsynthesis.
SB431542 (3M) decreased basal [3H]glucosamine incorporation
by 43% and TGF--mediated [3H]glucosamine incorporation by
72% (p 0.01) (Fig. 4A) indicating inhibition of ALK5-mediated
GAG synthesis of VSMC proteoglycans.
TGF- Increases Proteoglycan Core Protein Synthesis via the
ALK/Smad2/3 Pathway—[35S]Met/Cys incorporation was
assessed to investigate changes in total proteoglycan core pro-
tein synthesis. TGF- increased [35S]Met/Cys incorporation by
35% compared with control (p 0.01) indicating an increase in
core protein synthesis. SB431542 (3 M) decreased basal
FIGURE 2.p38MAPkinase inhibitors block TGF--mediatedGAGelonga-
tion in human VSMCs. VSMCs were treated with SB203580 (1–10 M),
SB202190 (1–10 M), SB202474 (1–10 M), and SB431542 (3 M) in the pres-
ence of TGF- (2 ng/ml) and [35S]sulfate (50 Ci/ml) for 24 h. A, medium
containing secreted proteoglycanswas spotted onto chromatography paper
and CPC precipitated to assess radiolabel incorporation. Results are the
mean S.E. of data normalized to control from three separate experiments in
triplicate. ##, p  0.01 versus control, and **, p  0.01 versus TGF- alone,
using a one-way ANOVA. B, secreted proteoglycans were isolated using ion-
exchange chromatography (DEAE-Sephacel) and concentrated by ethanol
precipitation. Electrophoretic mobility of complete proteoglycans was
assessed by SDS-PAGE on a 4–13% acrylamide gradient gel. The gel is repre-
sentative of three identical experiments. C, GAG chains were chemically
cleaved as described under “Experimental Procedures” and separated by
SDS-PAGE on a 4–20% acrylamide gel. The gel is representative of three anal-
yses from three separate experiments.
FIGURE 3. Temporal effects of SB431542 on TGF-/ALK5-mediated pro-
teoglycan synthesis inhumanVSMCs.A, VSMCswere treatedwith TGF- (2
ng/ml) and SB431542 (SB) (3M) and radiolabeled with [35S]sulfate (100Ci/
ml) for 6, 12, 18, and 24 h. Medium containing secreted proteoglycans was
spotted onto chromatography paper and CPC precipitated to assess radiola-
bel incorporation into proteoglycans. The experiment was performed twice,
and a representative is shown. B, secreted proteoglycans were isolated using
ion-exchange chromatography (DEAE-Sephacel) and concentrated by etha-
nol precipitation. Electrophoretic mobility of proteoglycans was assessed by
SDS-PAGE on a 4–13% acrylamide gradient gel. The gel is representative of
two identical experiments.
Smad and p38 Signaling of Proteoglycan Synthesis
MARCH 21, 2008•VOLUME 283•NUMBER 12 JOURNAL OF BIOLOGICAL CHEMISTRY 7847
 at UQ Library - St.Lucia on July 17, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
[35S]Met/Cys incorporation by 12% and TGF--mediated
[35S]Met/Cys incorporation by 27% (p 0.01) (Fig. 4B) indicat-
ing inhibition of ALK5-mediated proteoglycan core protein
synthesis.
Inhibition of ALK5 Blocks TGF--induced GAG Elongation
Dependently and Independently of Proteoglycan Core Proteins—
To assess whether the changes in proteoglycan size that we
observed were specifically because of alterations in GAG
length, we chemically cleaved the GAG chains from proteogly-
can core proteins. The electrophoreticmobility of cleavedGAG
chainswas greater comparedwith complete proteoglycans (Fig.
5A). In the presence of TGF- the cleaved GAG chains showed
a decrease in electrophoretic mobility compared with control,
indicating an increased size. Electrophoretic mobility of GAG
chains in TGF--treated cells was inhibited to control levels in
the presence of 3 M SB431542 (Fig. 5A). These changes were
definitively evaluated by size exclusion chromatography. A rep-
resentative size exclusion analysis experiment is shown where
FIGURE 4. ALK5 inhibition blocks the effects of TGF- on glucosamine
incorporation into proteoglycans and total proteoglycan core protein
synthesis inhumanVSMCs.A, VSMCswere treatedwithTGF- (2 ng/ml) and
SB431542 (SB) (3 M) and radiolabeled with [3H]glucosamine (10 Ci/ml) for
24 h. Medium containing secreted proteoglycans was spotted onto chroma-
tography paper and CPC precipitated to assess radiolabel incorporation into
GAGs. Results shown are the mean S.E. of normalized data from three sep-
arate experiments in triplicate. ##, p  0.01 versus control, and **, p  0.01
versus TGF-, using a one-way ANOVA. B, VSMCs were treated with TGF- (2
ng/ml) and SB431542 (3 M) and radiolabeled with [35S]Met/Cys (50 Ci/ml)
for 24 h to assess total proteoglycan core protein synthesis. Medium contain-
ing secreted proteoglycans was spotted onto chromatography paper and
CPCprecipitated to assess radiolabel incorporation into coreproteins. Results
shown are the mean  S.E. of normalized data from three separate experi-
ments in triplicate. ##, p 0.01 versus control, and **, p 0.01 versus TGF-
using a one-way ANOVA.
FIGURE 5. Inhibition of ALK5 signaling prevents TGF--induced GAG
chain synthesis and elongation in human VSMCs. VSMCs were treated
with TGF- (2 ng/ml) andSB431542 (3M). [35S]Sulfate (50Ci/ml)was added
4 h post-treatment and proteoglycans radiolabeled for a further 24 h.
Secreted proteoglycans were isolated using ion-exchange chromatography
(DEAE-Sephacel) and concentrated by ethanol precipitation. GAG chains
were chemically cleaved by incubation in 1 M NaBH4, 0.05 M NaOH at 45 °C for
24 h. A, electrophoretic mobility of intact proteoglycans and chemically
cleaved GAG chains assessed by SDS-PAGE on a 4–20% acrylamide gradient
gel. The gel is representative of three identical experiments. B, size exclusion
chromatography of cleaved GAG chains was performed using a Sepharose
CL-6B column. The dotted vertical line indicates Kav of cleaved GAG chains
from control cells. Three measures were performed from three separate
experiments, and a representative is shown. ##, p 0.01 versus control, and
**, p 0.02 versus TGF- using a paired Student’s t test. SB, SB431542.
Smad and p38 Signaling of Proteoglycan Synthesis
7848 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 12•MARCH 21, 2008
 at UQ Library - St.Lucia on July 17, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the vertical line represents the mean Kav of GAG chains from
control cells (Fig. 5B). GAG chains from TGF--treated cells
have a Kav value of 0.39  0.01 compared with control (p 
0.01), where Kav is 0.42  0.01, indicating TGF--mediated
GAGelongation. Inhibition of ALK5with SB431542 resulted in
aKav of 0.44 0.02 comparedwithTGF- treatment alone (p
0.02), indicating that SB435142 inhibited TGF- stimulation of
GAG elongation.
We used -D-xyloside (an initiator of GAG synthesis) to
examine GAG synthesis independently of core protein synthe-
sis. TGF- (2 ng/ml) increased [35S]sulfate incorporation by
169% compared with control (p 0.01) (Fig. 6A). SB431542 (3
M) decreased basal [35S]sulfate incorporation by 24% and
TGF--mediated [35S]sulfate incorporation by 64% (p  0.01)
(Fig. 6A). Xyloside-initiated GAG chains were separated by
SDS-PAGE. Electrophoretic mobility of xyloside-initiated pro-
teoglycans in the presence of TGF- was reduced compared
with control (Fig. 6B, lanes 2 and 4). Inhibition of ALK5 by
SB431542 prevented the effect of TGF- on proteoglycan syn-
thesis and had the same electrophoretic mobility when com-
pared with control (Fig. 6B, lane 5). Complete proteoglycans
also may be seen at the top of the gel. As determined by size
exclusion chromatography, xyloside-initiated GAG chains
from TGF--treated cells have a Kav value of 0.52 0.02 com-
pared with control cells (p  0.05) which have a Kav of 0.62 
0.01 (p 0.05), demonstrating an increase inGAG length in the
presence of TGF-. Treatment with SB431542 resulted in aKav
of 0.60 compared with TGF- treatment alone (p 0.05), ver-
ifying that SB435142 inhibited TGF--mediated stimulation of
GAG synthesis.
SB431542 Inhibits PDGF-mediated GAG Synthesis but Not
VSMC Proliferation—To examine the specificity of SB431542,
we evaluated its action on the tyrosine kinase growth factor,
PDGF. It was expected that at the concentration specific for
ALK5 inhibition (3 M), there would be no effect on PDGF.
PDGF (50 ng/ml) stimulated [35S]sulfate incorporation by 82%
relative to control (p  0.01) (Fig. 7). Treatment of cells with
SB431542 (0–3 M) showed a concentration-dependent
decrease of PDGF-mediated [35S]sulfate incorporation into
secreted proteoglycans (Fig. 7A) with a maximum decrease of
60% at 3M (p  0.01). Imatinib, a protein-tyrosine kinase
inhibitor (26) that inhibits PDGF-mediated GAG elongation,3
was used as a positive control and inhibited PDGF-mediated
[35S]sulfate incorporation by 97% (p 0.01) (Fig. 7A). Separa-
tion of proteoglycans on SDS-PAGE showed a concentration-
dependent increase in electrophoretic mobility in the presence
of SB431542 relative to PDGF treatment alone (Fig. 7B), indi-
cating a concentration-dependent decrease in proteoglycan
size upon treatment with SB431542.
The effect on VSMC mitogenic response as a classic PDGF
cellular action was assessed to investigate whether SB431542
would inhibit PDGFR-mediated responses (Fig. 7C). PDGF
caused a 170% increase in [3H]thymidine incorporation com-
pared with control (p  0.01). No change in [3H]thymidine
incorporation was observed in the presence of SB431542, indi-
cating that SB431542 does not block the PDGFR and is not a
PDGFR tyrosine kinase inhibitor. Genistein, used here as a pos-
itive control, inhibited PDGF-mediated [3H]thymidine incor-
poration by 92% (p 0.01).
PDGF is known tomediate TGF- release fromVSMCs (27).
To investigate whether PDGF mediates the release of a func-
tional amount of TGF-, we used a neutralizing antibody to
block the effects of any TGF-. Cells were incubated with anti-
TGF-1/2/3 antibody (1–50-foldmolar excess) in the presence
of TGF- (2 ng/ml) to generate a concentration inhibition
curve (Fig. 8A). At both 10- and 50-fold molar excess, the anti-
TGF- antibody inhibited TGF--mediated [35S]sulfate incor-
poration into proteoglycans (p  0.01) (Fig. 8A). Mouse IgG,
used as an isotype control, had no effect on TGF--mediated
[35S]sulfate incorporation as expected. The anti-TGF- anti-
body (50-fold molar excess) showed no effect under basal con-
ditions (Fig. 8A). The effect of the antibody at 20-fold molar
excess was assessed against PDGF to investigate potential
PDGF-mediated TGF- release from VSMCs. The antibody
showed no effect under basal conditions. The antibody
3 M. L. Ballinger and P. J. Little, unpublished observations.
FIGURE 6. ALK5 inhibitor SB431542 blocks the effect of TGF- on xylo-
side-initiated GAG chain synthesis in human VSMCs. VSMCs were treated
with SB431542 (SB) (3 M) and TGF- (2 ng/ml). [35S]Sulfate (50 Ci/ml) was
added 4 h post-treatment, and proteoglycans were radiolabeled for 24 h. For
analysis of GAG synthesis independent of proteoglycan core protein, treat-
ment medium was supplemented with a “false acceptor,” 0.5 mM xyloside.
A, medium containing secreted proteoglycanswas spotted onto chromatog-
raphy paper and CPC precipitated to assess radiolabel incorporation. Results
shown are the mean  S.E. of normalized data from three separate experi-
ments in triplicate. ##, p 0.01 versus control, and **, p 0.01 versus TGF-,
using a one-way ANOVA. B, xyloside-initiated and -secreted GAGs were iso-
lated using ion-exchange chromatography (DEAE-Sephacel) and concen-
trated by ethanol precipitation. Electrophoretic mobility of xyloside-initiated
GAG chains was assessed by SDS-PAGE on a 4–16% acrylamide gradient gel.
The gel is representative of three identical experiments. C, size exclusion
chromatography of cleaved GAG chains was performed using a Sepharose
CL-6B column. Data are plotted as Kav against [
35S]sulfate (cpm). The dotted
vertical line indicates the Kav of xyloside-initiated GAG chains from control
cells. Three measures were performed from three separate experiments, and
a representative is shown. #, p  0.05 versus control, and *, p  0.05 versus
TGF-, using a paired Student’s t test.
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decreased PDGF (50 ng/ml)-mediated [35S]sulfate incorpora-
tion by 24% (p 0.05) (Fig. 8B), suggesting that such a TGF-
release may contribute to the action of PDGF on proteoglycan
synthesis in VSMCs. The antibody was used with TGF- as a
positive control and was found to decrease TGF--mediated
[35S]sulfate incorporation by 40% (Fig. 8B). Effects of the anti-
body on [35S]sulfate incorporation are mirrored on an SDS-
PAGE analysis (Fig. 8C). SB431542 (3 M) decreased PDGF-
mediated [35S]sulfate incorporation by 57% (Fig. 8B) and
increased electrophoretic mobility (Fig. 8C). The presence of
SB431542 and the antibody together in PDGF-treated cells did
not decrease [35S]sulfate incorporation any further (Fig. 8B).
The data indicate that SB431542 inhibits PDGF-mediated pro-
FIGURE 7. Determination of the specificity of action of SB431542 by
examining its effects on tyrosine kinase growth factor (PDGF)-activated
processes in human VSMCs. A, VSMCs were treated with PDGF (50 ng/ml)
and SB431542 (0–3 M) and radiolabeled with [3SS]sulfate (50 Ci/ml) for
24 h. Imatinib (1 M) was used as a positive control. Medium containing
secreted proteoglycans was spotted onto chromatography paper and CPC
precipitated to assess radiolabel incorporation. Results are themean S.E. of
data normalized to control from three experiments in triplicate. ##, p 0.01
versus control, and **, p  0.01 versus PDGF, using a one-way ANOVA.
B, secreted proteoglycans were isolated using ion-exchange chromatogra-
phy (DEAE-Sephacel) and concentrated by ethanol precipitation. Electro-
phoretic mobility of proteoglycans was assessed by SDS-PAGE on a 4–13%
acrylamide gradient gel. The gel is representative of three identical experi-
ments. C, human VSMCs were treated with PDGF (50 ng/ml) and SB431542
(0–3 M) for 16 h followed by the addition of [3H]thymidine (1 Ci/ml) for a
further 3 h. Genistein (100 M) was used as a positive control. Cells were
washed with ice-cold phosphate-buffered saline, incubated with HClO4
(0.2 M), and digested with NaOH (0.2 M). Results are the mean  S.E. of data
normalized to control from three experiments in triplicate. ##, p 0.01 versus
control, and **, p 0.01 versus PDGF, using a one-way ANOVA.
FIGURE 8.Effects of ananti-TGF-1/2/3 antibodyonPDGF-mediatedpro-
teoglycan synthesis in human VSMCs. A, VSMCs were incubated with anti-
human-TGF-1/2/3 monoclonal antibody (mAb; 1–50-fold molar excess) for
40 min prior to treatment with TGF- (2 ng/ml) and radiolabeling with
[35S]sulfate (50 Ci/ml). Mouse IgG was used as an isotype control. Medium
containing secreted proteoglycanswas spotted onto chromatography paper
and CPC precipitated to assess radiolabel incorporation. Results are the
mean S.E.. ##, p 0.01 versus control, and **, p 0.01 versus TGF- alone,
using a one-way ANOVA. B, VSMCswere incubatedwith anti-human-TGF-1/
2/3 monoclonal antibody (Ab; 20-fold molar excess) prior to treatment with
PDGF (50 ng/ml) and SB431542 (3 M) in the presence of [35S]sulfate (50
Ci/ml). TGF- was used as a positive control. Radiolabel incorporation was
assessed as described under “Experimental Procedures.” Results are the
mean  S.E. of data normalized to control from three experiments in tripli-
cate. ##, p 0.01 versus control, *, p 0.05 versus PDGF, **, p 0.01 versus
PDGF, and, p 0.01 versus TGF-, using a one-way ANOVA. C, secreted
proteoglycans were isolated using ion-exchange chromatography (DEAE-
Sephacel) and concentrated by ethanol precipitation. Electrophoretic mobil-
ity of proteoglycans was assessed by SDS-PAGE on a 4–13% acrylamide gra-
dient gel. The gel is representative of three identical experiments. SB,
SB431542.
Smad and p38 Signaling of Proteoglycan Synthesis
7850 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 12•MARCH 21, 2008
 at UQ Library - St.Lucia on July 17, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
teoglycan synthesis in VSMCs and may inhibit an autocrine
effect of TGF- released following PDGF stimulation.
Inhibition of ALK5 and p38 MAP Kinase Reduces LDL Bind-
ing to Proteoglycans from TGF--treated Human VSMCs—Gel
mobility shift assays were performed to assess proteoglycan-
LDL binding. Proteoglycans derived from cells treated with
SB431542 (3M) under basal conditions had similar LDL bind-
ing to control proteoglycans (data not shown). However, pro-
teoglycans derived from SB431542-treated cells in the presence
of TGF- had a decreased binding to LDL compared with
TGF- treatment alone (p  0.001) with half maximal satura-
tion values of 50 and 25g/ml LDL, respectively (Fig. 9A). Sim-
ilarly, proteoglycans from SB202190-treated cells in the pres-
ence of TGF- exhibited decreased LDL binding compared
with TGF- treatment (p 0.05) (Fig. 9B), indicating that inhi-
bition of TGF--mediated signaling via ALK5/Smad2/3 or p38
MAP kinase results in proteoglycans with a decreased propen-
sity to bind LDL.
DISCUSSION
A TGF--activated Smad2/3 phosphorylation pathway is
present in human internal mammary artery-derived VSMCs
and, alongwith p38MAPkinase signaling, is responsible for the
TGF--mediated elongation of GAG chains on proteoglycans.
Inhibiting Smad2/3 phosphorylation with SB431542 antago-
nized the GAG elongation action of TGF-, and inhibition of
p38 kinase also blocked TGF--mediated GAG elongation.
Further investigation revealed that SB431542 partially inhib-
ited the GAG elongation action of another atherogenic growth
factor, PDGF.However, we demonstrated that this latter action
was likely due to the PDGF-stimulated autocrine secretion of
functional levels of TGF- and that SB431542 has no direct
action to inhibit a classic PDGFR-mediated response such as
VSMCproliferation (28). Finally, inhibition of phosphorylation
of Smad2/3 and p38MAPkinasewith SB431542 and SB202190,
respectively, reversed TGF--mediated increases in proteogly-
can/LDL binding.
TGF- is a secreted cytokine that controls a plethora of cel-
lular processes, including cell proliferation, differentiation,
apoptosis, extracellular matrix production, and immune func-
tions (9, 10, 14, 29). TGF- signals through Ser/Thr kinase
receptors type I (TRI/ALK 5) and type II (TR II) (9, 10) and
subsequently the Smad proteins (11–14). TGF- stimulates the
synthesis of elongated GAG chains on VSM proteoglycans (7,
30). Elongation of GAG chains on VSM proteoglycans is of
particular interest in cardiovascular disease because it leads to
enhanced binding of proteoglycans to lipoproteins on LDL
(7, 21).
It has been shown definitively that, in the early stages of
human atherosclerosis, the pathological process begins with
lipid deposition in the basal layers of diffuse intimal thickenings
(6). Interestingly, the lipid deposition described in early athero-
sclerotic lesions occurs in association with enrichment of the
proteoglycan biglycan (6). As such, proteoglycan synthesis, and
specifically GAG synthesis, represents a potential therapeutic
target (6, 21). Recent advances in elucidation of TGF- signal-
ing pathways may provide insights into possible therapeutic
strategies for the future (18).
The use of small specific inhibitors developed for therapeu-
tics can be a powerful tool in dissecting complex signal trans-
duction pathways (31). This study focused on TGF- signaling
by the use of a potentALK5 inhibitor, SB431542 (31). SB431542
also inhibits the ALK4 and ALK7 receptors, which are highly
related to ALK5 in their kinase domains, but it has no effect on
any of the other ALKs (24). SB431542 acts by competitively
inhibitingATP binding. It inhibits TGF-- and activin-induced
phosphorylation of Smad2 and Smad3, which is mediated by
ALK4/5/7 (24). SB431542 has previously been shown to pre-
vent TGF--induced gene expression of collagen, plasminogen
activator inhibitor-1, and connective tissue growth factor (32).
Future studies will enable us to obtain a clearer picture of the
effects of this inhibitor on gene transcriptional events related to
proteoglycans in VSM. Our findings show SB431542 to be useful
as a novel experimental tool for gaining understanding of TGF-
signaling leading to proteoglycan synthesis in VSMCs. Further
studies using antibodies to individual Smads or a commercially
available inhibitorofALK5-mediatedSmad3phosphorylationwill
further define and delineate these signaling pathways.
Very little is known about the signaling biochemistry operat-
ing between cell surface receptors and the ultimate changes in
FIGURE 9. ALK5 and p38 MAP kinase inhibition reduces LDL binding to
proteoglycans derived from TGF--treated human VSMCs. VSMCs were
treated with TGF- (2 ng/ml) and the ALK5 inhibitor SB431542 (3 M) (A) or
the p38 MAP kinase inhibitor SB202190 (10 M) (B), and core proteins were
radiolabeled with [35S]Met/Cys (50 Ci/ml). Core protein-radiolabeled pro-
teoglycans were isolated and equal counts combined with increasing con-
centrations of LDL. Flat-bed agarose gels were utilized for separation of
bound and free proteoglycans in the presence of TGF- and SB431542 or
SB202190. Calculation of bound proteoglycans was performed using image
analysis software with the results shown as the mean S.E. from two exper-
iments analyzed in duplicate. ***, p 0.001, and *, p 0.05, using a two-way
interactive ANOVA.
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GAG synthesis and structure. PDGF stimulates GAG elonga-
tion and the expression of mRNA for proteoglycan core pro-
teins, but only the increased expression of the core protein ver-
sican is blocked by the broad spectrum protein-tyrosine kinase
inhibitor genistein (30, 33). Genistein inhibits PDGF-activated
VSMC proliferation (28). The fact that GAG elongation stimu-
lated by PDGF is not blocked by genistein suggests that a novel
signaling pathway dependent upon the PDGFR but independ-
ent of its tyrosine kinase activity is responsible for mediating
GAG elongation in VSMCs. This observation generated our
interest in the signaling pathway by which TGF- stimulated
GAG elongation in VSMCs, which revealed that TGF--medi-
atedGAGelongation proceeds via a knownALK5 and Smad2/3
pathway.
InVSMCTGF--mediated activation of p38MAPkinase has
been shown to induce expression of thrombospondin (34), vas-
cular endothelial growth factor (35) and is involved in induction
of smoothmusclemarker genes (36). AlthoughTGF-has been
demonstrated to regulate biglycan expression via p38 MAP
kinase in the pancreatic adenocarcinoma cell line PANC-1 (16,
17), in the present study we have described an involvement of
p38MAP kinase in TGF--mediated proteoglycan synthesis in
VSMCanddemonstrated that inhibition of this pathway results
in proteoglycans with decreased LDL binding. Using two p38
MAP kinase inhibitors at concentrations that enable highly
specific inhibition, the results clearly demonstrate a role for p38
MAP kinase in TGF- signaling in ALK5-mediated GAG syn-
thesis. We observed inhibition of GAG chain elongation by
both the Smad inhibitor and the p38 inhibitors. It remains an
interesting question as to the relationship between Smad2/3
and p38 MAP kinase, particularly whether or not p38 MAP
kinase is downstream and therefore Smad-dependent or is oth-
erwise a Smad-independent pathway. A recent report in human
cardiac fibroblasts has shown that TGF- induction of GAG
synthesis occurs through both ALK5 and p38 signaling (37).
Further studies will facilitate the identification of the signaling
intermediates that dictate TGF--mediated effects on proteo-
glycans in VSMCs, including the possible downstream associa-
tion of p38MAP kinase to upstream Smad2/3 phosphorylation.
Although molecular manipulations that interfere with
TGF- signaling lead to deleterious actions on the immune
system in animal models, there are very little data available on
the impact of small molecule TGF- inhibitors (38). Compared
with the molecular genetics approach, these agents may either
be more specific in their action or indeed favorably less effica-
cious in inhibiting TGF- signaling. Small molecule inhibitors
provide an opportunity to evaluate the potential of inhibiting
growth factor signaling pathways for the prevention of changes
in the synthesis and structure ofVSMCproteoglycans. The data
provided in this paper indicate that a suitable TGF- signaling
inhibitor should be evaluated for its potential to prevent lipid
deposition and atherosclerosis.
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